Daratumumab,Talquetamab,Teclistamab,Pomalidomide,tocilizumab
Genmab,Janssen,jw pharma,roche
['mmsm', 'toci']
aa3/all crs were g1/2; 78%; onset 2-3 days! toci was used in 55% of those who had crs hematological toxicity g3/4: anemia 28%, neutropenia 28%, thrombocytopenia: 22% #mmsm #myeloma #medtwitter #meded #asco23 #usmirc 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter